Hubble Therapeutics is a biotechnology company focused on developing gene therapies to treat pediatric blindness. Their lead candidate, HUB-101, targets rare eye disorders such as Leber Congenital Amaurosis (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), both caused by mutations in the KCNJ13 gene. The therapy aims to address the underlying causes of these severe retinal dystrophies, which typically manifest in early childhood and lead to progressive vision loss.
Leadership & Board
Current Number of Employees2
Current LinkedIn Followers378
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$7M
Total Amount Raised$7M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$7M
Latest Funding Amount$7M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Hubble Therapeutics had 2 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
2Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Hubble Therapeutics had 378 followers as of October 5, 2026. The number of followers increased by 2 (0.53%) week-over-week.
378Latest Followers Count
2(0.53%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Mar 25, 2025
Series A
$7.30M
―
Similar Companies
A snapshot of private companies similar to Hubble Therapeutics, helping you discover and navigate related company profiles.